Diversity of aminoglycoside modifying enzymes and 16S rRNA methylases in Acinetobacter baumannii and Acinetobacter nosocomialis species in Iran; wide distribution of aadA1 and armA

Salimizand, Himen; Zomorodi, Abolfazl Raafati; Mansury, Davood; Khakshoor, Mostafa; Azizi, Omid; Khodaparast, Sepideh; Baseri, Zohre; Karami, Pezhman; Zamanlou, Sajjad; Farsiani, Hadi; Amini, Yousef; Moradi, Bagher; Meshkat, Zahra; Salimizand, Hana; Hasanzadeh, Sepideh; Sadeghian, Hamid

doi:10.1016/j.meegid.2018.09.028

Cited by 18 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gentamicin and tobramycin retain activity because of their inability to accept phosphate secondary to a lack of 3 -hydroxyl groups [198]. A. baumannii isolates may produce a combination of AMEs, as in a PDR A. baumannii strain described in China and carrying four AMEs [199]. Among others, AAC(3)-Ia, ANT(2')-Ia, and ANT(3")-Ia are variants of AMEs described in A. baumannii [186,200,201].…”

Section: Aminoglycosidesmentioning

confidence: 99%

“…Efflux pump overactivity RND pump AdeABC, AdeIJK, and AcrAB-TolC [179][180][181][182][183][184][185] Tet pump TetA and TetB [180] Ribosomal protection Tetracycline dissociation from ribosome Tet(O) and Tet(M) [180,[186][187][188] Fluoroquinolones Target mutation DNA gyrase GyrA [191,192] DNA topoisomerase IV ParC [191,192] Efflux pump overactivity RND pump AdeABC [81,191] MATE family AbeM [194] Aminoglycosides Drug inactivating enzymes Aminoglycoside modifying enzymes AAC(3)-Ia [185] AAC(3 )-Ia [200] ANT(2 )-Ia [200] ANT(3")-Ia [199] Target mutation 16sRNA methylase genes armA, rmtA, rmtB, rmtC, and rmtD [197,201] Efflux pump overactivity RND pumps AdeABC [175,202] Macrolides Efflux pump overactivity SMR pump AbeS [204] Polymyxins…”

Section: Tertacyclinesmentioning

confidence: 99%

See 1 more Smart Citation

Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen

2020

View full text Add to dashboard Cite

Being a multidrug-resistant and an invasive pathogen, Acinetobacter baumannii is one of the major causes of nosocomial infections in the current healthcare system. It has been recognized as an agent of pneumonia, septicemia, meningitis, urinary tract and wound infections, and is associated with high mortality. Pathogenesis in A. baumannii infections is an outcome of multiple virulence factors, including porins, capsules, and cell wall lipopolysaccharide, enzymes, biofilm production, motility, and iron-acquisition systems, among others. Such virulence factors help the organism to resist stressful environmental conditions and enable development of severe infections. Parallel to increased prevalence of infections caused by A. baumannii, challenging and diverse resistance mechanisms in this pathogen are well recognized, with major classes of antibiotics becoming minimally effective. Through a wide array of antibiotic-hydrolyzing enzymes, efflux pump changes, impermeability, and antibiotic target mutations, A. baumannii models a unique ability to maintain a multidrug-resistant phenotype, further complicating treatment. Understanding mechanisms behind diseases, virulence, and resistance acquisition are central to infectious disease knowledge about A. baumannii. The aims of this review are to highlight infections and disease-producing factors in A. baumannii and to touch base on mechanisms of resistance to various antibiotic classes.

show abstract

Section: Aminoglycosidesmentioning

confidence: 99%

Section: Tertacyclinesmentioning

confidence: 99%

Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen

2020

View full text Add to dashboard Cite

show abstract

“…Depending on the mechanism by which it acts, AMEs are classified into acetyltransferases, phosphotransferases and nucleotidyl transferases [ 161 , 162 ]. The main AMEs involved in AGR in A. baumannii are aac (3′)-I , aph (3′)-I , aph (3′)-VI , aac (6′)-Ib , ant (2″)-Ia, ant (3′)–I , aac(3)-Ia [aacC1], aac(3)-IIa [aacC2], aac(6′)-Ib [aacA4], aac(6′)-Ih, aac(6′)-Im, aph(3′)-Ia [aphA1], aph(3′) -VIa [aphA6], ant(3″)Ia [aadA1] and ant(2″)-Ia [aadB] , aac(6′)-I ad, aac(6′)-II and ant(4′)-I [ 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 ]. Genes encoding AMEs can be transferred as part of gene cassettes in the case of integrons, as well as through conjugation mechanisms [ 174 ].…”

Section: Short Characterization Of the Molecular Mechanisms Of Armentioning

confidence: 99%

“…Enzymatic modification of AGs through production of aminoglycoside-modifying enzymes (AMEs) is the main mechanism of resistance in A. baumannii. Depending on the mechanism by which it acts, AMEs are classified into acetyltransferases, phosphotransferases and nucleotidyl transferases [161,162] 6)-II and ant(4 )-I [163][164][165][166][167][168][169][170][171][172][173]. Genes encoding AMEs can be transferred as part of gene cassettes in the case of integrons, as well as through conjugation mechanisms [174].…”

Section: Enzymatic Mechanismsmentioning

confidence: 99%

Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii

et al. 2020

View full text Add to dashboard Cite

Antibiotic resistance is one of the biggest challenges for the clinical sector and industry, environment and societal development. One of the most important pathogens responsible for severe nosocomial infections is Acinetobacter baumannii, a Gram-negative bacterium from the Moraxellaceae family, due to its various resistance mechanisms, such as the β-lactamases production, efflux pumps, decreased membrane permeability and altered target site of the antibiotic. The enormous adaptive capacity of A. baumannii and the acquisition and transfer of antibiotic resistance determinants contribute to the ineffectiveness of most current therapeutic strategies, including last-line or combined antibiotic therapy. In this review, we will present an update of the antibiotic resistance profiles and underlying mechanisms in A. baumannii and the current progress in developing innovative strategies for combating multidrug-resistant A. baumannii (MDRAB) infections.

show abstract

“…Kanamycin is widely used in the treatment of animal infections, added as growth promoters or feed additives for preventive therapy [1]. The antibacterial mechanism of kanamycin is that it can irreversibly bind to the bacterial ribosomal 30S subunit and inhibit its protein synthesis [2]. Because of its potential ototoxicity and nephrotoxicity [3,4,5,6], the indiscriminate use of kanamycin will enhance bacterial resistance and cause kanamycin-residue accumulation in animal-derived food, which threatens human health.…”

Section: Introductionmentioning

confidence: 99%

Determination of Kanamycin by High Performance Liquid Chromatography

Zhang

Wang

et al. 2019

Molecules

View full text Add to dashboard Cite

Kanamycin is an aminoglycoside antibiotic widely used in treating animal diseases caused by Gram-negative and Gram-positive infections. Kanamycin has a relatively narrow therapeutic index, and can accumulate in the human body through the food chain. The abuse of kanamycin can have serious side-effects. Therefore, it was necessary to develop a sensitive and selective analysis method to detect kanamycin residue in food to ensure public health. There are many analytical methods to determine kanamycin concentration, among which high performance liquid chromatography (HPLC) is a common and practical tool. This paper presents a review of the application of HPLC analysis of kanamycin in different sample matrices. The different detectors coupled with HPLC, including Ultraviolet (UV)/Fluorescence, Evaporative Light Scattering Detector (ELSD)/Pulsed Electrochemical Detection (PED), and Mass Spectrometry, are discussed. Meanwhile, the strengths and weaknesses of each method are compared. The pre-treatment methods of food samples, including protein precipitation, liquid-liquid extraction (LLE), and solid-phase extraction (SPE) are also summarized in this paper.

show abstract

Diversity of aminoglycoside modifying enzymes and 16S rRNA methylases in Acinetobacter baumannii and Acinetobacter nosocomialis species in Iran; wide distribution of aadA1 and armA

Cited by 18 publications

References 18 publications

Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen

Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen

Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii

Determination of Kanamycin by High Performance Liquid Chromatography

Contact Info

Product

Resources

About